Condition: Hypertriglyceridemia · Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.
This description comes directly from the study's public registry record.
Miaomiao Shi · 18036617171 · Miaomiao.shi@hengrui.com
Always discuss trial participation with your own doctor first.
| Zhongshan Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07349615